WXXWY and 1FW2 Related Headlines
Go Back- WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
- WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
- WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
- WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
- WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
- WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
- WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
- WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
- WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
- WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
- WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
- WuXi Biologics Reports Record 2025 Annual Results
- World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
- WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
- WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
- WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
- WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
- JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
- WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
- WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
- WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
- WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
- WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
- WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
- WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
- WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
- WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
- WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
- WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
- Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
- WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
- WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
- WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
- WuXi Biologics Reports Solid 2025 Interim Results
- WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
- WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
- WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
- WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
- WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
WXXWY and 1FW2 Related Press Releases
Go Back- WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
- WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
- WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
- WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
- WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
- WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
- WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
- WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
- WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
- WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
- WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
- WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
- WuXi Biologics Reports Record 2025 Annual Results
- World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
- WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
- WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
- WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
- WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
- JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
- WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
- WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
- WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
- WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure
- WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
- WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
- WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
- WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan
- WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
- WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
- WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
- Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
- WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
- WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
- WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
- WuXi Biologics Reports Solid 2025 Interim Results
- WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
- WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
- WuXi Biologics Named to A List for CDP Supplier Engagement Assessment
- WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
- WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
